Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) Director Sells 2,000 Shares of Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) Director Lawson Macartney sold 2,000 shares of the business's stock in a transaction on Friday, November 8th. The stock was sold at an average price of $68.67, for a total value of $137,340.00. Following the transaction, the director now directly owns 47,965 shares in the company, valued at $3,293,756.55. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Viking Therapeutics Stock Down 0.5 %

VKTX stock traded down $0.37 during midday trading on Friday, hitting $68.48. The company's stock had a trading volume of 3,878,237 shares, compared to its average volume of 4,505,156. The firm has a market capitalization of $7.63 billion, a P/E ratio of -73.42 and a beta of 1.00. Viking Therapeutics, Inc. has a 52-week low of $9.34 and a 52-week high of $99.41. The firm has a 50-day simple moving average of $64.68 and a 200-day simple moving average of $61.85.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last issued its quarterly earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.02. During the same period in the previous year, the company posted ($0.23) EPS. On average, sell-side analysts expect that Viking Therapeutics, Inc. will post -0.98 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on VKTX. Morgan Stanley reissued an "overweight" rating and set a $105.00 price target on shares of Viking Therapeutics in a research report on Thursday, September 12th. HC Wainwright increased their price objective on Viking Therapeutics from $90.00 to $102.00 and gave the stock a "buy" rating in a research report on Monday. StockNews.com upgraded Viking Therapeutics to a "sell" rating in a research report on Tuesday, October 15th. Raymond James raised their price objective on Viking Therapeutics from $116.00 to $118.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 25th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $138.00 target price on shares of Viking Therapeutics in a research report on Wednesday, September 25th. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $109.80.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Oak Ridge Investments LLC purchased a new stake in shares of Viking Therapeutics during the 3rd quarter worth $837,000. Nvwm LLC acquired a new position in shares of Viking Therapeutics during the 3rd quarter worth about $999,000. Nepsis Inc. acquired a new position in shares of Viking Therapeutics during the 3rd quarter worth about $11,251,000. CWM LLC increased its holdings in shares of Viking Therapeutics by 70.6% in the 2nd quarter. CWM LLC now owns 1,518 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 628 shares during the last quarter. Finally, Raymond James & Associates raised its position in shares of Viking Therapeutics by 43.2% during the 3rd quarter. Raymond James & Associates now owns 441,590 shares of the biotechnology company's stock worth $27,957,000 after acquiring an additional 133,144 shares in the last quarter. Institutional investors and hedge funds own 76.03% of the company's stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.